Segment Reporting

9 Months Ended

Jul. 31, 2018

Segment Reporting [Abstract]

Segment Reporting

17. SEGMENT REPORTING

The Company’s operations involve dissimilar products which are managed separately. Accordingly, it operates in two segments: 1) regenerative medicine and 2) veterinary sciences.

Certain information concerning our segments for the three and nine months ended July 31, 2018 and 2017 and as of July 31, 2018 and 2017 is presented in the following table (in thousands):

	Three Months Ended July 31,
	2018			2017
Revenues:
Reportable Segments:
Regenerative Medicine	$	244		$	—
Veterinary Sciences		172			—
Discontinued Operations		—			—
Total consolidated revenues	$	416		$	—
Net loss:
Reportable Segments:
Regenerative Medicine	$	(17,157	)	$	(5,267	)
Veterinary Sciences		(88	)		—
Discontinued Operations		—			67
Total net loss	$	(17,245	)	$	(5,200	)

	Nine Months Ended July 31,
	2018			2017
Revenues:
Reportable Segments:
Regenerative Medicine	$	260		$	—
Veterinary Sciences		172			—
Discontinued Operations		—			—
Total consolidated revenues	$	432		$	—
Net loss:
Reportable Segments:
Regenerative Medicine	$	(42,865	)	$	(120,872	)
Veterinary Sciences		(88	)		—
Discontinued Operations		—			(349	)
Total net loss	$	(42,953	)	$	(121,221	)

	As of July 31, 2018		As of October 31, 2017
Identifiable assets employed:
Reportable Segments:
Regenerative Medicine	$	93,577	$	20,152
Veterinary Sciences		4,310		—
Discontinued Operations		—		—
Total assets	$	97,887	$	20,152